Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
“Jazz continues to be committed to deepening our understanding of sleep disorders and delivering transformational medicines to those with lifelong and chronic sleep conditions,” says Robert Iannone, MD, MSCE, executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals, in a release. “There remains a large unmet need for people living with sleep disorders, including narcolepsy and idiopathic hypersomnia, and we look forward to showcasing the latest research and results from our portfolio during SLEEP 2021 as we work to help people with sleep disorders live fuller lives.”
Highlights from Jazz at SLEEP 2021 will include the following presentations:
- A late-breaking abstract poster presentation on June 13 on a sub-group analysis of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution compared to placebo in adults with idiopathic hypersomnia with long sleep time (n=25) and without long sleep time (n=91), and the importance of treatment effects on those two groups
- Additional data results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measures of sleep parameters
- Results from a real-world study of the cardiovascular burden of narcolepsy
- Data results from the titration and administration (START) study of Sunosi (solriamfetol) in patients with narcolepsy
Xywav is not currently approved by regulatory authorities for the treatment of idiopathic hypersomnia.
Find a full list of Jazz-supported data below:
Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution Oral Presentation and Posters | ||
Presentation Title | Author | Presentation Date / Time (EDT) & Number |
Correlation of the Idiopathic Hypersomnia Severity Scale Score With Other Measures of Sleep Parameters in a Phase 3 Trial | Dauvilliers et al. | Oral PresentationSunday, June 13 12:41-12:52 PMAbstract ID: 500 |
Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia | Dauvilliers et al. | ePoster PresentationAbstract ID: 494 |
Efficacy and Safety of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia: With and Without Long Sleep Time | Bogan et al. | ePoster PresentationAbstract ID: LBA070 |
Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study | Bogan et al. | ePoster PresentationAbstract ID: 487 |
Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia | Arnulf et al. | ePoster PresentationAbstract ID: 485 |
Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale | Foldvary-Schaefer et al. | ePoster PresentationAbstract ID: 495 |
Clinical Presentation Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Retrospective, Real-World Claims Analysis | Saad et al. | ePoster PresentationAbstract ID: 497 |
Utilization of Diagnostic Sleep Testing Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Real-World Claims Analysis | Saad et al. | ePoster PresentationAbstract ID: 499 |
Timing and Duration of Adverse Events in a Clinical Trial of Lower-Sodium Oxybate in Participants With Narcolepsy With Cataplexy | Bogan et al. | ePoster PresentationAbstract ID: 486 |
Cardio-Vascular Burden of Narcolepsy Disease (CV-BOND): A Real-World Evidence Study | Ben-Joseph et al. | ePoster PresentationAbstract ID: 503 |
Sunosi® (solriamfetol) Poster Presentations | ||
Presentation Title | Author | Presentation Number |
Solriamfetol Titration & Administration (START): Characteristics of Patients With Narcolepsy and Solriamfetol Prescriber Rationale | Thorpy et al. | ePoster PresentationAbstract ID: 481 |
Solriamfetol Titration & Administration (START): Dosing and Titration Strategies in Patients With Narcolepsy Starting Solriamfetol | Thorpy et al. | ePoster PresentationAbstract ID: 482 |
Solriamfetol Titration & Administration (START): Physician Titration Strategies in a Hypothetical Patient With Narcolepsy | Singh et al. | ePoster PresentationAbstract ID: 484 |
Additionally, data from the following investigator-sponsored trials will be presented as poster presentations: | ||
Presentation Title | Author | Presentation Number |
Impact of A Single Sleep Education Session on Beliefs and Attitudes Among People with Excessive Daytime Sleepiness: A Pilot Study | Grandner et al. | ePoster PresentationAbstract ID: 089 |
Strategies for Dealing with or Ameliorating Excessive Sleepiness: Beliefs and Attitudes of People with Daytime Sleepiness | Grandner et al. | ePoster PresentationAbstract ID: 090 |
Seeking Treatment for Daytime Sleepiness: Beliefs and Attitudes Among People with Excessive Daytime Sleepiness | Grandner et al. | ePoster PresentationAbstract ID: 120 |
It Makes Relationships Harder: The Role of Narcolepsy in Social and Romantic Relationships in Young Adults | Zhou et al. | ePoster PresentationAbstract ID: 498 |
The Effect of Sodium Oxybate on Cataplexy in Orexin -/- Mice | Hamieh et al | ePoster PresentationAbstract ID: 006 |